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Transforming growth factor β 1 (TGFB1) likely contributes to the pathogenesis
of Epstein-Barr virus (EBV)-mediated cancer. A microarray containing 59 probes for
detecting mRNA of members of TGFB1-associated pathways was developed. mRNA
expression of TGFB1 receptors and members of connected pathways were examined
in peripheral blood leukocytes of patients during acute EBV infection and after
recovery. TGFB1 and TGFBR2mRNA expression was increased in patients with EBV
infection. Similarly, mRNA expression of protein kinase C (PRKCB), MAP3K7,
PDLIM7, and other members of TGFB1 and NF-κB signaling pathways increased.
A shift of mRNA transcript variant expression of some key members (TGFBR2,
PRKCB, and NFKBIB) of involved signaling pathways was detected. After the
patients’ recovery, most of the altered mRNA expression has been normalized. We
speculate that in patients with EBV infection, members of TGFB1-associated path-
ways contribute to the suppression of proapoptotic and induction of pro-survival
factors in leukocytes. The modulation of TGFB1-associated pathways may be
considered as a potential risk factor in the development of EBV-associated tumors
in patients with acute EBV infection.
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Introduction
Epstein-Barr virus (EBV, Human gammaherpesvirus 4) is a ubiquitous
human oncogenic virus that persists in over 90% of the world’s population. It is
known that EBV makes a signiﬁcant contribution to several human cancers, such
as B-cell, T-cell, and NK-cell lymphomas [1].
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Transforming growth factor β 1 (TGFB1) is a multifunctional polypeptide that
plays a critical role in the regulation of cell proliferation, differentiation, and growth
[2]. It induces EBV lytic infection by activating the expression of EBV’s latent-lytic
switch BZLF1 gene through the canonical SMAD pathway [3]. TGFB1might provide
a signiﬁcant contribution to the transforming potential of EBV. In patients with EBV-
associated nasopharyngeal carcinomas, high serum level of TGFB1 is an unfavorable
prognostic [4], for it can enhance tumor progression by stimulating epithelial-
mesenchymal transition [5]. On the other hand, in EBV-infected gastric epithelial
cell lines, TGFB1 mediates growth inhibition and apoptosis [6].
The dual nature of TGFB1 is determined by its ability to crosstalk with
MAPK8 and NF-κB signal pathways (hereafter ofﬁcial full names of genes are
provided in Supplementary Table I; available at https://cloud.nniiem.ru/s/
1FdiA0LgZEOrNtV) [7–9]. Regulatory molecules like protein kinase C PRKCB
are capable of preventing TGFB1-dependent apoptosis in tumor cells by suppres-
sion of activity of transcription modulator SMAD3 [10] and activation of MAPK8
and NF-κB signaling pathway, thereby promoting cell survival [11–13]. In
addition, for some members of TGFB1-associated pathways, multiple mRNA
transcript variants with different functions are identiﬁed.
All of the above make it difﬁcult to assess the contribution of TGFB1 to the
development of EBV-associated pathology. Expression pattern of members of
TGFB1-connected pathways in blood cells of patients with non-oncological EBV
infection is currently poorly understood. Simultaneously, this knowledge will
improve our understanding of the mechanisms of transformation of infected cells
and will offer new strategies for the therapy of EBV-associated cancer.
The aim of this study was to examine the expression pattern of members of
TGFB1-associated pathways in leukocytes of patients with acute EBV infection.
Materials and Methods
A microarray design was developed using “Splice variants microarray
design pipeline” algorithm [14]. A total of 59 target probes were selected including
23 gene “total mRNA” probes (designed to detect all mRNA transcript variants of
one gene) and 36 “mRNA transcript variant” probes (designed to detect one
speciﬁc mRNA transcript variant of one gene; Supplementary Table I). Seventy
“negative control” probes, design based on Rhizobium rubi genome, were
included in each microarray. Microarray design was adapted for probe synthesis
using Layout Designer software (CustomArray Inc., WA, USA). Probe synthesis
was conducted in situ on the 12K microarray slides by the B3 Synthesizer
(CustomArray Inc.). The synthesis and post-synthetic slide deprotection were
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carried out in accordance with the manufacturer’s protocols using recommended
reagents.
Blood samples were obtained from 7- to 18-year-old (median= 12) patients
diagnosed with infectious mononucleosis. Acute EBV infection was conﬁrmed by
clinical symptoms and laboratory tests (ELISA and PCR). Blood samples were
taken in acute phase of infection (EBVinf, n= 6) before the beginning of
symptomatic drug therapy, which included, by prescription, ibuprofen, acetamin-
ophen, and xylometazoline, and 2 months after apparent clinical recovery
(EBVrec, n= 5). Due to the high similarity of the pathogenesis mechanism and
symptoms of the disease, children of 8–17 (median= 11) years old with conﬁrmed
acute Human herpesvirus 6 infection (HHV-6inf, n= 7 and HHV-6rec, n= 7)
were used as the comparison group. Another group comprised healthy volunteers
of 8–17 (median= 11) years old without clinical and laboratory signs of infection
(NORM, n= 17). All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the institutional and national
research committee and with the 1964 Helsinki Declaration and its later amend-
ments or comparable ethical standards. Informed consent was obtained from all
individual participants’ parents or legal guardians included in the study.
Blood samples were treated with a hemolytic solution (CRIE, Russia) to
remove red blood cells. From the obtained leukocyte fraction, total RNA was
isolated and proceeded to biotin-labeled antisense RNA according to common
protocols using commercial kits and reagents (Evrogen, Russia; DNA synthesis,
Russia; Thermo Scientiﬁc, EU). Hybridization of the labeled RNA on the
microchip and measurement of the amperometric signal were carried out using
a commercial set of ElectraSense reagents and equipment (CustomArray Inc.),
according to the manufacturer’s recommendations.
All further calculations were performed using R software (RStudio version
1.1.453, RStudio, Inc., Boston, MA, USA). Data were normalized using the subset
quantile normalization based on the non-speciﬁc control features [15]. To estimate
fold change, sample means of NORM and EBV were calculated for each target
probe. Fold change (%) was calculated as [(EBV sample mean× 100/NORM
sample mean)− 100]. For each target probe, NORM sample versus EBVinf sample
were tested using t-test; p= 0.05 was selected as threshold value. The same
procedures were performed using EBVrec, HHV-6inf, and HHV-6rec samples.
Results
It was shown that EBV infection was followed by change of expression
pattern of TGFB1 and TGFB1-connected pathways in human leukocytes
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Figure 1. Fold change of total mRNA expression of members of TGFB1-connected pathways in
leukocytes of patients with acute EBV infection (EBV) and after apparent clinical recovery (EBVrec)
in comparison with healthy volunteers. *Difference is statistically signiﬁcant (p< 0.05). For mRNA
transcript variants, see Supplementary Table I
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(Figure 1, Supplementary Table I, available at https://cloud.nniiem.ru/s/
1FdiA0LgZEOrNtV). TGFB1 total mRNA expression and mRNA transcript
variant 1 expression increased in EBVinf compared with NORM. After the
recovery, TGFB1 expression has been normalized.
Expression of some of the members of SMAD-mediated TGFB1 signaling
pathway was increased in EBVinf compared with healthy volunteers (NORM). In
EBVinf leukocytes TGFBR2 total mRNA expression and mRNA transcript variant
2 expression, SMAD2 mRNA transcript variant 2 expression increased. TGFBR1,
SMAD3, and SMAD4mRNA expression did not change in EBVinf compared with
NORM. In EBVrec, expression of mRNA of members of SMAD-mediated
TGFB1 signaling pathway did not differ compared with NORM, except for
SMAD2 mRNA transcript variant 2 expression, which remained elevated. In
EBVinf, PRKCB total mRNA expression and mRNA transcript variant 2 expres-
sion decreased compared with NORM. Apparent clinical recovery was accompa-
nied by normalization of PRKCB mRNA expression.
In EBVinf, MAP3K7 total mRNA expression increased compared with
NORM. This indicator returned to normal after clinical recovery. EBV infection
was not accompanied by the change in the mRNA expression of other participants
of MAPK8 signaling pathways (MAP3K11, MAP3K1, MAPK1, MAP2K4,
MAPK8, and JUN). TRAF6 total mRNA expression and expression of both
TRAF6 mRNA transcript variants decreased in EBVinf compared with NORM.
After recovery, the TRAF6 mRNA expression did not differ from NORM.
mRNA expression of some members of NF-κB signaling pathway was
modulated in leukocytes of patients with EBV infection. Among members of IKK
complex, CHUK, IKBKB, and ELP1 mRNA expression did not change, but
IKBKG total mRNA expression and mRNA transcript variants 3 and 4 expression
increased in EBVinf compared with NORM. After clinical recovery, IKBKG
mRNA transcript variant 4 expression remained elevated. Among NF-κB
inhibitors, NFKBIA mRNA expression did not change in patients with EBV.
NFKBIB total mRNA expression also did not change in EBVinf compared with
NORM, but NFKBIB mRNA transcript variants 1 and 2 expression increased,
whereas NFKBIB non-coding mRNA transcript variant 3 expression decreased.
NFKBIB mRNA transcript variants 1 and 2 expression remained elevated in
EBVrec, and NFKBIB non-coding mRNA transcript variant expression normal-
ized after recovery. Among NF-κB subunits, NFKB1 total mRNA expression,
NFKB1mRNA transcript variant 1 expression, and RELA total mRNA expression
increased, whereas NFKB1 mRNA transcript variant 3 expression decreased in
EBVinf compared with NORM. NFKB1 total mRNA expression and NFKB1
mRNA transcript variant 1 expression remained elevated after apparent clinical
recovery.
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We did not reveal similar mRNA expression pattern in children with acute
HHV-6 infection (Supplementary Table I).
Discussion
We speculate that revealed changes of mRNA expression pattern in leuko-
cytes of patients with EBV were caused by acute EBV infection. Our results also
suggest that members of TGFB1-associated pathways play signiﬁcant role in viral
pathogenesis. The revealed changes might be associated with suppression of
apoptosis and promotion of leukocytes’ proliferation through activation of protein
kinase C PRKCB (Figure 2) or/and modulation of mRNA transcript variants
expression of some key members (TGFBR2, PRKCB, and NFKBIB) of involved
signaling pathways.
Figure 2. mRNA expression of members of TGFB1-associated pathways in leukocytes of patients
with acute EBV infection. Thick arrows show changes in total mRNA expression of some members
of TGFB1-associated pathways in infected patients compared with healthy volunteers. Detected
mRNA expression pattern’s changes might result in inhibiting TGFB1-dependent apoptosis,
activation of NF-κB, and stimulation of cell proliferation
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Speciﬁcally, TGFBR2 mRNA transcript variant 2, which was highly
expressed in EBVinf leukocytes, is typically detected in leukemia cells where
it is associated with impaired cell differentiation and proliferation, as well as
suppression of apoptosis [16]. Expression of TGFBR2mRNA transcript variant 1,
which is able to stimulate TGBF1-dependent suppression of proliferation and
apoptosis in tumor cell lines [17], did not change in EBVinf. In this study, PRKCB
mRNA transcript variant 2 expression decreased in patients with EBV, and similar
results were observed in colorectal cancer cells in which PRKCBmRNA transcript
variant 2 isozyme reverses cell transformation. In patients with colorectal cancer,
low levels of PRKCB mRNA transcript variant 2 expression serve as a predictor
for poor survival outcome [18]. In addition, according to our ﬁndings, expression
of PRKCB mRNA transcript variant 1, which is directly involved in the MAPK
and NF-κB activation and cell proliferation, increased in EBVinf blood, although
it was not statistically signiﬁcant. Again, in EBVinf leukocytes, NFKBIB mRNA
expression pattern changed upward, since protein coding mRNA transcript variant
expression increased, whereas non-coding transcript variant expression decreased.
All the above contribute to the suppression of proapoptotic and induction of
pro-survival factors in leukocytes. The results allow us to consider the modulation
of TGFB1-associated pathways as a potential risk factor in the development of
EBV-associated tumors in patients with acute EBV infection.
The data sets generated and analyzed during this study are available from the
corresponding author on reasonable request.
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